AzTrials
AzTrials

SchizophreniaPILOT-SSP-SCZNCT07671040

A Pilot Study of Adjunctive Structured Supportive Psychotherapy in Schizophrenia

A study testing Structured supportive psychotherapy, Risperidone and Unstructured Supportive Conversation in people with Schizophrenia and Cognitive and Executive Dysfunction, run by Hasanuddin University at 1 site in Indonesia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This pilot randomized controlled trial examined whether adding structured supportive psychotherapy to risperidone treatment is more effective than risperidone alone in improving cognitive function and reducing peripheral inflammation in stabilized inpatients with schizophrenia. Read more about this study

Who is it for?
Ages 20 to 45 years
What is being tested?
Structured supportive psychotherapy, Risperidone and Unstructured Supportive Conversation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
44 participants
Where
1 siteIndonesia
Study dates
1 Mar 2025to 30 Jun 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Male and female inpatients diagnosed with schizophrenia according to DSM-5-TR criteria
  • Aged 20 to 45 years
  • In a post-acute stabilized residual phase
  • Total PANSS score between 60 and 70
  • Receiving risperidone at a fixed dose of 4 mg per day
  • Willing and able to attend individual psychotherapy sessions throughout the 12-week trial period

Who cannot join

  • Febrile conditions at time of screening
  • Organic comorbid diseases
  • Active infectious diseases
  • Obesity (body mass index ≥ 30 kg/m²)
  • Comorbid personality disorders
  • Concurrent use of anti-inflammatory medications or antioxidant supplements
  • Substance use disorder within the preceding 6 months

Trial locations and contacts

1 site in 1 country.

Indonesia1 site
  • Department of Psychiatry, Faculty of Medicine, Hasanuddin University

    Makassar, South Sulawesi, 90245

Other trials in Indonesia

About this study

Official title: Effects of Adjunctive Structured Supportive Psychotherapy on Cognitive Function and Serum High-Sensitivity C-Reactive Protein in Schizophrenia: A Pilot Randomized Controlled Trial

This pilot randomized controlled trial examined whether adding structured supportive psychotherapy to risperidone treatment is more effective than risperidone alone in improving cognitive function and reducing peripheral inflammation in stabilized inpatients with schizophrenia.

Forty-four male and female inpatients with schizophrenia were randomly assigned to two groups: the intervention group (n=22) received risperidone 4 mg/day plus 12 individual sessions of structured supportive psychotherapy (45-60 minutes per session, once weekly) over 12 weeks. The control group (n=22) received risperidone 4 mg/day plus 12 sessions of unstructured supportive conversation (attention-matched) over the same 12-week period.

Read more

Cognitive function was measured using the Montreal Cognitive Assessment - Indonesian version (MoCA-Ina) and inflammation was measured using serum high-sensitivity C-reactive protein (hs-CRP) levels, both assessed at baseline (Week 0) and after treatment (Week 12).

NOTE: This pilot randomized controlled trial was retrospectively registered. The study was conducted from March 2025 to June 2025 and received ethical clearance (PROTOKOL-UH24100793) from Komite Etik Penelitian Universitas Hasanuddin, prior to study initiation. Registration was performed after study completion due to the investigator's initial unawareness of prospective registration requirements. No outcome measures, study design, or statistical analysis plan were modified following data collection.

Read the detailed description

This single-center, assessor-blinded, parallel-group pilot randomized controlled trial (RCT) was conducted at a national-level referral psychiatric hospital in South Sulawesi, Indonesia, with laboratory analyses performed at a university-affiliated molecular research laboratory in the same province, from March 2025 to June 2025.

BACKGROUND:

Schizophrenia affects approximately 23.6 million individuals globally and is associated with significant cognitive impairment spanning seven Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) domains, with affected patients performing approximately two standard deviations below healthy controls. A landmark network meta-analysis of 68 randomized controlled trials (RCTs) confirmed that no antipsychotic yields cognitive benefits superior to placebo, establishing a clear pharmacological ceiling. Converging evidence further implicates neuroinflammatory dysregulation as a key mechanistic contributor to cognitive burden, with elevated levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumor necrosis factor alpha (TNF-α) inversely associated with performance across five cognitive domains. hs-CRP is consistently elevated in schizophrenia and tracks illness-stage severity, establishing it as a biologically plausible peripheral neuroinflammatory biomarker. While structured psychosocial interventions demonstrate meaningful adjunctive benefits in low-resource settings, no published RCT had examined whether adjunctive structured supportive psychotherapy simultaneously improves cognition and reduces peripheral neuroinflammatory burden in schizophrenia. This pilot RCT was designed to address that gap.

INTERVENTION:

Both groups received fixed-dose risperidone 4 mg/day throughout the 12-week trial period, with adherence ensured via direct nursing observation. The intervention arm additionally underwent 12 individual structured supportive psychotherapy sessions delivered once weekly over 12 weeks, each lasting 45-60 minutes (total therapist contact time approximately 540-720 minutes), conducted by three board-certified psychiatrists each with over five years of psychotherapy experience, using the nationally validated Indonesian supportive psychotherapy module for schizophrenia. The active control arm received an equivalent number of individual sessions over the same 12-week period (12 sessions, once weekly, each lasting 45-60 minutes), delivered by three board-certified psychiatrists with equivalent clinical experience, yielding comparable total therapist contact time of approximately 540-720 minutes per participant. Control sessions consisted of unstructured supportive conversation without a session manual, predetermined therapeutic modules, structured psychoeducation, or a fidelity protocol.

PARTICIPANTS AND ELIGIBILITY:

Eligible participants were male and female inpatients aged 20 to 45 years, diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria, who were in a post-acute stabilized residual phase on a fixed dose of risperidone 4 mg/day, and scored between 60 and 70 on the total Positive and Negative Syndrome Scale (PANSS). Exclusion criteria included febrile conditions, organic comorbidities, active infections, obesity (body mass index ≥ 30 kg/m²), personality disorders, concurrent anti-inflammatory or antioxidant medications, and substance use disorder within the preceding 6 months.

RANDOMIZATION AND BLINDING:

Participants were allocated 1:1 to intervention or control using a computer-generated random number sequence managed by an independent researcher not involved in clinical recruitment. Allocation concealment was maintained through sequentially numbered opaque sealed envelopes (SNOSE), opened only after baseline assessments were completed. Randomization was not stratified by sex or baseline biomarker values in this pilot; stratified allocation will be incorporated in the planned multicenter trial. The study employed an assessor-blinded design. Outcome assessors evaluating MoCA-Ina scores and laboratory personnel measuring serum hs-CRP levels were strictly blinded to group assignments throughout the study period. Both arms received equivalent standard inpatient psychiatric care, equivalent therapist contact time, and equivalent therapist qualification, with group assignment differing solely in the presence or absence of structured manualized therapeutic content. As is inherent to psychotherapy research, participant blinding was not possible; however, participants were not formally asked to guess their allocation. The integrity of assessor blinding was not quantitatively evaluated in this pilot, a limitation to be addressed through formal blinding index assessment in future trials.

OUTCOME MEASURES:

Co-primary outcomes were: (1) change in cognitive function assessed by the MoCA-Ina from baseline (Week 0) to Week 12; and (2) change in serum hs-CRP level from baseline to Week 12. An exploratory secondary outcome was the Spearman correlation between change in hs-CRP (Δhs-CRP, where Δ denotes Week 12 minus baseline) and change in MoCA-Ina score (ΔMoCA-Ina) within each group at Week 12. PANSS change scores were also assessed as an additional secondary outcome to evaluate differential symptomatic improvement between arms.

ETHICAL APPROVAL:

This study was approved by Komite Etik Penelitian Universitas Hasanuddin (PROTOKOL-UH24100793), and conducted in accordance with the 2013 Declaration of Helsinki. Written informed consent was obtained from all participants or their legally authorized representatives prior to enrollment, with explicit assurance that withdrawal at any point would carry no adverse consequence. This manuscript contains no individually identifiable participant information.

NOTE: This pilot randomized controlled trial was retrospectively registered. The study was conducted from March 2025 to June 2025 and received ethical clearance (PROTOKOL-UH24100793) from Komite Etik Penelitian Universitas Hasanuddin, prior to study initiation. Registration was performed after study completion due to the investigator's initial unawareness of prospective registration requirements. No outcome measures, study design, or statistical analysis plan were modified following data collection.

Being tested
Structured supportive psychotherapy, Risperidone, Unstructured Supportive Conversation
Keywords
Schizophrenia, Psychotherapy, Cognition, C-Reactive Protein, Neuroinflammation
Medical subject headings
Schizophrenia, Neuroinflammatory Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Structured supportive psychotherapyBehavioural

    Structured supportive psychotherapy using the Supportive Psychotherapy Module for Schizophrenia, nationally validated in the Indonesian population. Sessions progressed across three structured phases: Sessions 1-3 established therapeutic alliance and clinical formulation; Sessions 4-9 addressed psychoeducation, coping strategies, reality testing, and adherence reinforcement; and Sessions 10-12 consolidated treatment gains and planned relapse prevention. Protocol fidelity required completion of at least 10 of 12 sessions, monitored by an independent rater using a structured checklist (inter-rater agreement κ = 0.84).

  • RisperidoneDrug

    Risperidone 4 mg/day (2 mg tablet twice daily, oral administration) for 12 weeks

  • Unstructured Supportive ConversationBehavioural

    Participants in the active control arm received an identical schedule of individual sessions over the 12-week period, administered by three board-certified psychiatrists of comparable clinical expertise. This design ensured an equivalent total contact time of approximately 540-720 minutes per participant, consisting strictly of Standard Clinical Care with Active Control

Study groups in NCT07671040
Study groupRoleWhat they receive
Structured Supportive Psychotherapy plus RisperidoneExperimentalThe intervention arm additionally underwent 12 individual structured supportive psychotherapy sessions delivered once weekly over 12 weeks, each lasting 45-60 minutes (total therapist contact time approximately 540-720 minutes), conducted by three board-certified psychiatrists each with over five years of psychotherapy experience, using the nationally validated Indonesian supportive psychotherapy module for schizophrenia.
Receives: Behavioral: Structured supportive psychotherapy; Drug: Risperidone
Unstructured Supportive Conversation plus RisperidoneActive comparatorThe active control arm received an equivalent number of individual sessions over the same 12-week period (12 sessions, once weekly, each lasting 45-60 minutes), delivered by three board-certified psychiatrists with equivalent clinical experience, yielding comparable total therapist contact time of approximately 540-720 minutes per participant. Control sessions consisted of unstructured supportive conversation without a session manual, predetermined therapeutic modules, structured psychoeducation, or a fidelity protocol.
Receives: Drug: Risperidone; Behavioral: Unstructured Supportive Conversation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Cognitive Function (MoCA-Ina Score)

    Change in cognitive function assessed by the Montreal Cognitive Assessment - Indonesian version (MoCA-Ina) from baseline to Week 12. Score range 0-30; higher scores indicate better cognitive function. The MoCA-Ina is a World Health Organization (WHO)-aligned, nationally validated instrument with substantial inter-rater reliability (Cohen's kappa, κ = 0.820) and domain-level inter-rater agreement (κ = 0.817-1.000). Scores ≥26 indicate normal cognitive function.

    Measured: Baseline (Week 0) and post-intervention (Week 12)

  2. Change in Serum hs-CRP Level

    Change in serum high-sensitivity C-reactive protein (hs-CRP) level (mg/L) from baseline to Week 12, quantified using a sandwich Enzyme-Linked Immunosorbent Assay (ELISA) kit (Elabscience® Human hs-CRP ELISA Kit, catalog no. E-EL-H5134; detection range 15.63-1000 pg/mL; sensitivity 9.38 pg/mL; intra-assay coefficient of variation (CV) 4.47-4.64%; inter-assay CV 6.44-8.95%).

    Measured: Baseline (Week 0) and post-intervention (Week 12)

Secondary outcomes (2)
  1. Correlation Between Delta hs-CRP and Delta MoCA-Ina

    Correlation between change in serum hs-CRP level (Δhs-CRP) and change in cognitive function score (ΔMoCA-Ina) within each treatment group at Week 12. Analyzed using Spearman rank correlation coefficient (rho, ρ), with 95% confidence intervals derived via Fisher z-transformation. Delta values calculated as Week 12 minus Week 0 for each measure.

    Measured: Week 12 (end of intervention)

  2. Change in Positive and Negative Syndrome Scale (PANSS) Total and Subscale Scores

    Change in total PANSS score and subscale scores (positive, negative, and general psychopathology) from baseline to Week 12, assessed to evaluate differential symptomatic improvement between the intervention and active control arms. Between-group differences in change scores analyzed using independent-samples t-test or Mann-Whitney U test based on normality assessment (Shapiro-Wilk). Delta values calculated as Week 12 minus Week 0 for each subscale.

    Measured: Baseline (Week 0) and Week 12 (end of intervention)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jun 2026
  2. Study start1 Mar 2025
  3. Primary completion30 Jun 2025
  4. Study completion30 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
44 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07671040
Sponsor's protocol ID
PILOT-HSCRP-2025
Acronym
PILOT-SSP-SCZ
Status last verified
Jun 2026
First submitted
22 Jun 2026
Last updated
30 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared publicly. This pilot RCT involved a small sample (n=44) of psychiatric inpatients, raising re-identification risk despite de-identification efforts. The study was conducted at a single center in Indonesia without institutional data-sharing infrastructure. Findings from this pilot will inform a planned multicenter trial, which will include a formal prospective data-sharing plan.

Questions about this trial

What is this clinical trial studying?

A study testing Structured supportive psychotherapy, Risperidone and Unstructured Supportive Conversation in people with Schizophrenia and Cognitive and Executive Dysfunction, run by Hasanuddin University at 1 site in Indonesia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Cognitive Function (MoCA-Ina Score) (time frame: Baseline (Week 0) and post-intervention (Week 12)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in